Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.78 |
| ▸ | APP | P05067 | 3/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.78 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.78 |
| ▸ | CTSD | P07339 | 7/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10471338 | 1.00 | BACE1 (0.78) | BACE1APPCYP2D6BACE2CTSD | |
| SCHEMBL11432758 | 0.88 | BACE1 (0.76) | BACE1APPCYP2D6BACE2CTSD | |
| SCHEMBL15342789 | 0.88 | BACE1 (0.81) | BACE1APPCYP2D6BACE2CTSD | |
| SCHEMBL15345226 | 0.88 | BACE1 (1.00) | BACE1APPCYP2D6BACE2CTSD | |
| SCHEMBL10470848 | 0.85 | BACE1 (1.00) | BACE1APPCYP2D6BACE2CTSD | |
| SCHEMBL10473273 | 0.85 | BACE1 (1.00) | BACE1APPCYP2D6BACE2CTSD | |
| SCHEMBL16461770 | 0.84 | BACE1 (1.00) | BACE1APPCYP2D6BACE2CTSD | |
| SCHEMBL16461287 | 0.83 | BACE1 (0.88) | BACE1APPCYP2D6BACE2CTSD | |
| SCHEMBL15345200 | 0.83 | BACE1 (0.68) | BACE1APPCYP2D6BACE2CTSD | |
| SCHEMBL16461771 | 0.82 | BACE1 (0.87) | BACE1APPCYP2D6BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2663559-B1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | GRIK5, OTC, GRIN2C | BACE1 74/4885APP 148/4885CYP2D6 122/4885 |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | BACE1 2/4885APP 5/4885CYP2D6 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.